Richter’s Syndrome (RS): Emerging Therapeutic Horizons

Abstract

Purpose of Review: Richter's syndrome (RS) is an aggressive lymphoma that arises from pre-existing chronic lymphocytic leukemia (CLL). Despite significant advancements in CLL treatments over the last decade, including the emergence of novel therapies, RS continues to be associated with poor outcomes. In this review, we examine the current literature on RS and discuss the future research direction. Recent Findings: Traditional chemoimmunotherapy regimens in RS have been associated with generally poor outcomes. However, encouraging data emerged with the CAR-T cellular therapies, the CD20/CD3 bispecific antibodies and the combination of novel agents with chemoimmunotherapy. Summary: Richter's syndrome remains a therapeutic challenge with limited standard-of-care options. Advances in understanding its pathogenesis and the development of novel therapies hold promise for improving outcomes. Collaboration and ongoing clinical trials are essential to enhance treatment strategies for this aggressive complication of CLL.